The platelet P2 receptors in arterial thrombosis

Blood Cells, Molecules, and Diseases

Volumn 36, Issue 2, 2006, Pages 223-227

  Gachet, Christian ^a   Léon, Catherine ^a   Hechler, Béatrice ^a  

^a INSERM   (France)

Author keywords

ADP; Antiplatelet drugs; ATP; Clopidogrel; Haemostasis; P2X 1; P2Y12; P2Y1; Thrombosis

Indexed keywords

2' DEOXY 6 N METHYLADENOSINE 3',5' BISPHOSPHATE; ADENOSINE DIPHOSPHATE; ADENOSINE TRIPHOSPHATE; ANTICOAGULANT AGENT; ARC 66096; ARC 67085; ARC 69931; AZD 6140; CLOPIDOGREL; GUANINE NUCLEOTIDE BINDING PROTEIN; MRS 2500; PRASUGREL; PURINE P2 RECEPTOR; PURINE P2X RECEPTOR; PURINE P2Y RECEPTOR; PURINERGIC RECEPTOR BLOCKING AGENT; THROMBOCYTE RECEPTOR;

ARTERY THROMBOSIS; ARTICLE; HEMOSTASIS; HUMAN; PRIORITY JOURNAL; THROMBOCYTE AGGREGATION; THROMBOGENESIS;

ANIMALS; ARTERIAL OCCLUSIVE DISEASES; FIBRINOLYTIC AGENTS; HUMANS; PLATELET AGGREGATION; RECEPTORS, PURINERGIC P2; THROMBOSIS;

THROMBUS;

EID: 33645282277     PISSN: 10799796     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bcmd.2005.12.024     Document Type: Article

References (63)

1. A. Gaarder, J. Jonsen, and S. Laland Adenosine diphosphate in red cells as a factor in the adhesiveness of human blood platelets Nature 192 1961 531
2. G.V.R. Born Aggregation of blood platelets by adenosine diphosphate and its reversal Nature 194 1962 27
3. G.V. Born Adenosine diphosphate as a mediator of platelet aggregation in vivo: an editorial view Circulation 72 1985 741
4. J.P. Maffrand, A. Bernat, and D. Delebassee ADP plays a key role in thrombogenesis in rats Thromb. Haemost. 59 1988 225
5. V. Ralevic, and G. Burnstock Receptors for purines and pyrimidines Pharmacol. Rev. 50 1998 413
6. J.L. Gordon Extracellular ATP: effects, sources and fate Biochem. J. 233 1986 309
7. C. Gachet ADP receptors of platelets and their inhibition Thromb. Haemost. 86 2001 222
8. C. Léon, B. Hechler, and C. Vial The P2Y1 receptor is an ADP receptor antagonized by ATP and expressed in platelets and megakaryoblastic cells FEBS Lett. 403 1997 26
9. A. Baurand, P. Raboisson, and M. Freund Inhibition of platelet function by administration of MRS2179, a P2Y1 receptor antagonist Eur. J. Pharmacol. 412 2001 213
10. P. Mangin, P. Ohlmann, and A. Eckly The P2Y receptor plays an essential role in the platelet shape change induced by collagen when TxA2 formation is prevented J. Thromb. Haemost. 2 2004 969
11. C. Léon, B. Hechler, and M. Freund Defective platelet aggregation and increased resistance to thrombosis in purinergic P2Y(1) receptor-null mice J. Clin. Invest. 104 1999 1731
12. G. Hollopeter, H.M. Jantzen, and D. Vincent Identification of the platelet ADP receptor targeted by antithrombotic drugs Nature 409 2001 202
13. P. Savi, and J.M. Herbert Clopidogrel and ticlopidine: P2Y12 adenosine diphosphate-receptor antagonists for the prevention of atherothrombosis Semin. Thromb. Hemost. 31 2005 174
14. M. Cattaneo The P2 receptors and congenital platelet function defects Semin. Thromb. Hemost. 31 2005 168
15. C. Gachet Regulation of platelet functions by P2 receptors and their inhibition Annu. Rev. Pharmacol. Toxicol. 46 2006 277
16. G. Kauffenstein, B. Hechler, J.P. Cazenave, and C. Gachet Adenine triphosphate nucleotides are antagonists at the P2Y12 receptor J Thromb. Haemost. 2 2004 1980
17. E.T. Bodor, G.L. Waldo, and S.B. Hooks Purification and functional reconstitution of the human P2Y12 receptor Mol. Pharmacol. 64 2003 1210
18. P.B. Conley, and S.M. Delaney Scientific and therapeutic insights into the role of the platelet P2Y12 receptor in thrombosis Curr. Opin. Hematol. 10 2003 333
19. B. Hechler, M. Cattaneo, and C. Gachet The P2 receptors in platelet function Semin. Thromb. Hemostasis 31 2005 150
20. M. Cattaneo, A. Lecchi, and R. Lombardi Platelets from a patient heterozygous for the defect of P2CYC receptors for ADP have a secretion defect despite normal thromboxane A2 production and normal granule stores: further evidence that some cases of platelet 'primary secretion defect' are heterozygous for a defect of P2CYC receptors Arterioscler., Thromb., Vasc. Biol. 20 2000 E101
21. B. Hechler, A. Eckly, and P. Ohlmann The P2Y1 receptor, necessary but not sufficient to support full ADP-induced platelet aggregation, is not the target of the drug clopidogrel Br. J. Haematol. 103 1998 858
22. P. Savi, P. Beauverger, and C. Labouret Role of P2Y1 purinoceptor in ADP-induced platelet activation FEBS Lett. 422 1998 291
23. J. Jin, and S.P. Kunapuli Coactivation of two different G protein-coupled receptors is essential for ADP-induced platelet aggregation Proc. Natl. Acad. Sci. U. S. A. 95 1998 8070
24. C. Léon, C. Ravanat, and M. Freund Differential involvement of the P2Y1 and P2Y12 receptors in platelet procoagulant activity Arterioscler., Thromb., Vasc. Biol. 23 2003 1941
25. C. Léon, M. Alex, and A. Klocke Platelet ADP receptors contribute to the initiation of intravascular coagulation Blood 103 2004 594
26. R.F. Storey, H.M. Sanderson, and A.E. White The central role of the P(2T) receptor in amplification of human platelet activation, aggregation, secretion and procoagulant activity Br. J. Haematol. 110 2000 925
27. C. Léon, M. Freund, and C. Ravanat Key role of the P2Y(1) receptor in tissue factor-induced thrombin-dependent acute thromboembolism: studies in P2Y(1)-knockout mice and mice treated with a P2Y(1) antagonist Circulation 103 2001 718
28. M.P. Mahaut-Smith, G. Tolhurst, and R.J. Evans Emerging roles for P2X1 receptors in platelet activation Platelets 15 2004 131
29. M.G. Rolf, C.A. Brearley, and M.P. Mahaut-Smith Platelet shape change evoked by selective activation of P2X1 purinoceptors with alpha,beta-methylene ATP Thromb. Haemost. 85 2001 303
30. B. Hechler, N. Lenain, and P. Marchese A role of the fast ATP-gated P2X1 cation channel in thrombosis of small arteries in vivo J. Exp. Med. 198 2003 661
31. M. Cattaneo, P. Marchese, K.A. Jacobson, and Z. Ruggeri New insights into the role of P2X1 in platelet function Haematologica 87 2002 13
32. C. Oury, E. Toth-Zsamboki, and C. Thys The ATP-gated P2X1 ion channel acts as a positive regulator of platelet responses to collagen Thromb. Haemost. 86 2001 1264
33. C. Vial, M.G. Rolf, M.P. Mahaut-Smith, and R.J. Evans A study of P2X(1) receptor function in murine megakaryocytes and human platelets reveals synergy with P2Y receptors Br. J. Pharmacol. 135 2002 363
34. S.O. Sage, E.H. Yamoah, and J.W. Heemskerk The roles of P(2X1)and P(2T AC)receptors in ADP-evoked calcium signalling in human platelets Cell Calcium 28 2000 119
35. P. Savi, J.M. Pereillo, and M.F. Uzabiaga Identification and biological activity of the active metabolite of clopidogrel Thromb. Haemost. 84 2000 891
36. C. Gachet, M. Cattaneo, and P. Ohlmann Purinoceptors on blood platelets: further pharmacological and clinical evidence to suggest the presence of two ADP receptors Br. J. Haematol. 91 1995 434
37. Z. Ding, S. Kim, and R.T. Dorsam Inactivation of the human P2Y12 receptor by thiol reagents requires interaction with both extracellular cysteine residues, Cys17 and Cys270 Blood 101 2003 3908
38. P. Savi, M.C. Laplace, and J.M. Herbert Evidence for the existence of two different ADP-binding sites on rat platelets Thromb. Res. 76 1994 157
39. D.C. Mills, R. Puri, and C.J. Hu Clopidogrel inhibits the binding of ADP analogues to the receptor mediating inhibition of platelet adenylate cyclase Arterioscler. Thromb. 12 1992 430
40. Y. Niitsu, J.A. Jakubowski, A. Sugidachi, and F. Asai Pharmacology of CS-747 (prasugrel, LY640315), a novel, potent antiplatelet agent with in vivo P2Y12 receptor antagonist activity Semin. Thromb. Hemost. 31 2005 184
41. J.J. van Giezen, and R.G. Humphries Preclinical and clinical studies with selective reversible direct P2Y12 antagonists Semin. Thromb. Hemost. 31 2005 195
42. M. Cattaneo Aspirin and clopidogrel: efficacy, safety, and the issue of drug resistance Arterioscler., Thromb., Vasc. Biol. 24 2004 1980
43. T.A. Nguyen, J.G. Diodati, and C. Pharand Resistance to clopidogrel: a review of the evidence J. Am. Coll. Cardiol. 45 2005 1157
44. B. Aleil, C. Ravanat, and J.P. Cazenave Flow cytometric analysis of intraplatelet VASP phosphorylation for the detection of clopidogrel resistance in patients with ischemic cardiovascular diseases J. Thromb. Haemost. 3 2005 85
45. P.A. Gurbel, K.P. Bliden, B.L. Hiatt, and C.M. O'Connor Clopidogrel for coronary stenting: response variability, drug resistance, and the effect of pretreatment platelet reactivity Circulation 107 2003 2908
46. I. Muller, F. Besta, and C. Schulz Prevalence of clopidogrel non-responders among patients with stable angina pectoris scheduled for elective coronary stent placement Thromb. Haemost. 89 2003 783
47. P. Barragan, J.L. Bouvier, and P.O. Roquebert Resistance to thienopyridines: clinical detection of coronary stent thrombosis by monitoring of vasodilator-stimulated phosphoprotein phosphorylation Catheter. Cardiovasc. Interv. 59 2003 295
48. S. Matetzky, B. Shenkman, and V. Guetta Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction Circulation 109 2004 3171
49. A.H. Ingall, J. Dixon, and A. Bailey Antagonists of the platelet P2T receptor: a novel approach to antithrombotic therapy J. Med. Chem. 42 1999 213
50. R.F. Storey, K.G. Oldroyd, and R.G. Wilcox Open multicentre study of the P2T receptor antagonist AR-C69931MX assessing safety, tolerability and activity in patients with acute coronary syndromes Thromb. Haemost. 85 2001 401
51. R.F. Storey, R.G. Wilcox, and S. Heptinstall Comparison of the pharmacodynamic effects of the platelet ADP receptor antagonists clopidogrel and AR-C69931MX in patients with ischaemic heart disease Platelets 13 2002 407
52. F. Jacobsson, E. Swahn, L. Wallentin, and M. Ellborg Safety profile and tolerability of intravenous AR-C69931MX, a new antiplatelet drug, in unstable angina pectoris and non-Q-wave myocardial infarction Clin. Ther. 24 2002 752
53. J.L. Boyer, R.I. Patel, and J.G. Douglass Development of reversible P2Y12 receptor antagonists Haematologica 89 2004 13
54. J.L. Boyer, A. Mohanram, and E. Camaioni Competitive and selective antagonism of P2Y1 receptors by N6-methyl 2′-deoxyadenosine 3′,5′-bisphosphate Br. J. Pharmacol. 124 1998 1
55. M. Cattaneo, A. Lecchi, and M. Ohno Antiaggregatory activity in human platelets of potent antagonists of the P2Y 1 receptor Biochem. Pharmacol. 68 2004 1995
56. B. Hechler, C. Nonne, and E.J. Roh MRS2500, a potent, selective and stable antagonist of the P2Y1 receptor, with strong antithrombotic activity in mice J. Pharmacol. Exp. Ther. 2005 10.1124/jpet.105.094037
57. J.E. Fabre, M. Nguyen, and A. Latour Decreased platelet aggregation, increased bleeding time and resistance to thromboembolism in P2Y1-deficient mice Nat. Med. 5 1999 1199
58. N. Lenain, M. Freund, and C. Léon Inhibition of localized thrombosis in P2Y1-deficient mice and rodents treated with MRS2179, a P2Y1 receptor antagonist J. Thromb. Haemost. 1 2003 1144
59. C. Nonne, N. Lenain, and B. Hechler Importance of platelet phospholipase Cgamma2 signaling in arterial thrombosis as a function of lesion severity Arterioscler., Thromb., Vasc. Biol. 25 2005 1293
60. N. Lenain, M. Freund, and B. Hechler The role of the P2Y1, P2Y12, and P2X1 platelet receptors in a laser induced model of arterial thrombosis in vivo J. Thromb. Haemost. XIX ISTH meeting, Burmingham, UK 2003 Abstr.
61. M.A. van Gestel, J.W. Heemskerk, and D.W. Slaaf In vivo blockade of platelet ADP receptor P2Y12 reduces embolus and thrombus formation but not thrombus stability Arterioscler., Thromb., Vasc. Biol. 23 2003 518
62. M.U. Kassack, K. Braun, and M. Ganso Structure-activity relationships of analogues of NF449 confirm NF449 as the most potent and selective known P2X1 receptor antagonist Eur. J. Med. Chem. 39 2004 345
63. B. Hechler, S. Magnenat, and M.L. Zighetti Inhibition of platelet functions and thrombosis through selective or nonselective inhibition of the platelet P2 receptors with increasing doses of NF449 J. Pharmacol. Exp. Ther. 314 2005 232